Substance / Medication

Iodoquinol

Overview

Active Ingredient
iodoquinol
RxNorm CUI
3435

Indications

Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); follicul

Labeler: KMM Pharmaceuticals, LLCUpdated: 2024-11-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacological interventions for the management of cystinuria: a systematic review.
Bhatt Nirmal Prasad, Deshpande Aniruddh Vijay, Starkey Malcolm Ronald · J Nephrol · 2024
PMID: 37957454Meta-AnalysisFull text (PMC)
Blastocystis sp. in Small Ruminants: A Universal Systematic Review and Meta-analysis.
Shams Morteza, Asghari Ali, Baniasad Maryam et al. · Acta Parasitol · 2022
PMID: 35834160Meta-Analysis
Cystinuria: clinical practice recommendation.
Servais Aude, Thomas Kay, Dello Strologo Luca et al. · Kidney Int · 2021
PMID: 32918941Meta-Analysis
The effect of additional drug therapy as metaphylaxis in patients with cystinuria: a systematic review.
Melessen Indra M, Henderickx Michaël M, Merkx Maria M et al. · Minerva Urol Nefrol · 2020
PMID: 32083421Meta-Analysis
Associating mutations causing cystinuria with disease severity with the aim of providing precision medicine.
Martell Henry J, Wong Kathie A, Martin Juan F et al. · BMC Genomics · 2017
PMID: 28812535Meta-AnalysisFull text (PMC)
Entering into 2.0 cystinuric management with a medical digital tool to monitor urine pH: a prospective, randomized study.
Angerri O, Gracia S, Rousaud F et al. · Actas Urol Esp (Engl Ed) · 2023
PMID: 37086842RCT
The Impact of Diet on Urinary Risk Factors for Cystine Stone Formation.
Siener Roswitha, Bitterlich Norman, Birwé Hubert et al. · Nutrients · 2021
PMID: 33561968RCTFull text (PMC)
Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.
Malieckal Deepa A, Modersitzki Frank, Mara Kristin et al. · Urolithiasis · 2019
PMID: 30980122RCTFull text (PMC)
The genetics of cystinuria - an update and critical reevaluation.
Abad Baucells Clàudia, Schönauer Ria, Halbritter Jan · Curr Opin Nephrol Hypertens · 2024
PMID: 38240263Review
Hydration and Nephrolithiasis in Pediatric Populations: Specificities and Current Recommendations.
Injeyan Maud, Bidault Valeska, Bacchetta Justine et al. · Nutrients · 2023
PMID: 36771434ReviewFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Diiodohydroxyquinoline (substance)
SNOMED CT
387355005
UMLS CUI
C0012341
RxNorm CUI
3435
Labeler
KMM Pharmaceuticals, LLC

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.